Determination of haloperidol and reduced haloperidol in human serum by liquid chromatography after fluorescence labeling based on the Suzuki coupling reaction

Analytical and Bioanalytical Chemistry

Volumn 386, Issue 3, 2006, Pages 719-724

  Kishikawa, Naoya ^a   Hamachi, Chiyuki ^a   Imamura, Yoshihiro ^b   Ohba, Yoshihito ^a   Nakashima, Kenichiro ^a   Tagawa, Yashuhiro ^b   Kuroda, Naotaka ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b Tagawa Sanatorium   (Japan)

Author keywords

Fluorescence derivatization; Fluorescent arylboronic acid; Haloperidol; Reduced haloperidol; Suzuki coupling reaction; Therapeutic drug monitoring

Indexed keywords

FLUORESCENCE DERIVATIZATION; FLUORESCENT ARYLBORONIC ACID; HALOPERIDOL; REDUCED HALOPERIDOL; SUZUKI COUPLING REACTIONS; THERAPEUTIC DRUG MONITORING;

ACETONITRILE; DERIVATIVES; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLITES; PROTEINS; REACTION KINETICS;

DRUG PRODUCTS;

4 (4 (4 CHLOROPHENYL) 4 HYDROXY 1 PIPERIDINYL) 1 (4 FLUOROPHENYL) 1 BUTANOL; 4-(4-(4-CHLOROPHENYL)-4-HYDROXY-1-PIPERIDINYL)-1-(4-FLUOROPHENYL)-1-BUTANOL; BORON DERIVATIVE; DIPHENYLBORATE; DRUG DERIVATIVE; HALOPERIDOL;

ARTICLE; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; DRUG MONITORING; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METHODOLOGY; OXIDATION REDUCTION REACTION; REFERENCE VALUE; REPRODUCIBILITY; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY;

BORON COMPOUNDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; FLUORESCENCE; HALOPERIDOL; HUMANS; MALE; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY;

EID: 33749018787     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-006-0755-0     Document Type: Article

References (19)

1. Yamaguchi M, Ishida J (1999) In: Toyo'oka T (ed) Modern derivatization methods for separation sciences. Wiley, Chichester, pp 99-108
2. Nakashima K (2003) Biomed Chromatogr 17:83-95
3. Fukushima T, Usui N, Santa T, Imai K (2003) J Pharm Biomed Anal 30:1665-1687
4. Uchiyama S, Santa T, Okiyama N, Fukushima T, Imai K (2001) Biomed Chromatogr 15:295-318
5. Kuroda N, Sugihara S, Sugihara Y, Wada M, Kishikawa N, Ohba Y, Nakashima K (2005) J Chromatogr A 1066:119-125
6. Miyaura N, Suzuki A (1995) Chem Rev 95:2457-2483
7. Suzuki A (1999) J Organomet Chem 576:147-168
8. Santamaria B, Perez M, Montera D, Madurga M, de Abajo FJ (2002) Eur Psychiatry 17:471-476
9. Lane HY, Lin HH, Hu OY, Chen CC, Jann MW, Chang WH (1997) Prog Neuropsychopharmacol Biol Psychiatry 21: 299-311
10. Korpi ER, Kleinman JE, Costakos DT, Linnoila M, Wyatt RJ (1984) Brain Res 11:259-269
11. Lane HY, Chang WH, Chang YC, Hu OYP, Lin HN, Chang WH, Jann MW, Hu WH (1997) Psychiatry Res 72:127-132
12. Walter S, Bauer S, Roots I, Brockmöler J (1998) J Chromatogr B 720:231-237
13. Pan L, Rosseel MT, Belpaire FM (1998) Ther Drug Monit 20:224-230
14. Arinobu T, Hattori H, Iwai M, Ishii A, Kumazawa T, Suzuki O, Seno H (2002) J Chromatgr B 776:107-113
15. Marquet HH, Verneuil B, Lotfi H, Dupuy JL, Pénicaut B, Lachåtre G (1997) J Chromatgr B 688:275-280
16. Fujii T, Hatanaka K, Sato G, Yaui Y, Arimoto H, Mitsutsuka (1996) J Chromatgr B 687:395-403
17. Fukuda R (2000) Prog Neuropsychopharmacol Biol Psychiatry 24:1299-1318
18. Wu AB, Huan MC, Ho HO, Yeh GC, Sheu MT (2004) Biomed Chromatogr 18:443-449
19. Kuroda N, Kawazoe K, Nakano H, Wada M, Nakashima K (1999) Luminescence 14:361-364